{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T10:33:12Z","timestamp":1768991592318,"version":"3.49.0"},"reference-count":12,"publisher":"Georg Thieme Verlag KG","issue":"09","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z Gastroenterol"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite the high effectiveness of direct-acting antivirals for the treatment of hepatitis C, a small proportion of patients do not respond to approved regimens. The combination regimen of SOF\/VEL\/VOX was recently approved for patients with failure to prior NS5A-based treatment. In this German real-world cohort including patients with cirrhosis (27.3\u200a%) and previous decompensation events, 12 weeks of SOF\/VEL\/VOX resulted in high virologic response rates irrespective of disease severity and prior DAA regimen. Adverse events were mostly mild or moderate and comparable to those seen in the approval studies.<\/jats:p>","DOI":"10.1055\/a-1217-7669","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T22:42:50Z","timestamp":1600468970000},"page":"841-846","source":"Crossref","is-referenced-by-count":9,"title":["Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of\u00a0previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R)"],"prefix":"10.1055","volume":"58","author":[{"given":"Heiner","family":"Wedemeyer","sequence":"first","affiliation":[{"name":"Leberstiftungs-GmbH Deutschland, Hannover, Germany"},{"name":"Hannover Medical School, Hannover, Germany"},{"name":"Essen University Hospital, University of Duisburg-Essen, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Vermehren","sequence":"additional","affiliation":[{"name":"Gastro-Praxis Wiesbaden, Wiesbaden, Germany"},{"name":"University Hospital Frankfurt, Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Serfert","sequence":"additional","affiliation":[{"name":"Leberstiftungs-GmbH Deutschland, Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Cornberg","sequence":"additional","affiliation":[{"name":"Hannover Medical School, Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albrecht","family":"Stoehr","sequence":"additional","affiliation":[{"name":"ifi-Institute for Interdisciplinary Medicine, Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartwig","family":"Klinker","sequence":"additional","affiliation":[{"name":"University Hospital W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl-Georg","family":"Simon","sequence":"additional","affiliation":[{"name":"MVZ Dres. Eisenbach, Simon, Schwarz GbR, Leverkusen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerlinde","family":"Teuber","sequence":"additional","affiliation":[{"name":"Hepatologische Schwerpunktpraxis, Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Deterding","sequence":"additional","affiliation":[{"name":"Hannover Medical School, Hannover, Germany"},{"name":"Essen University Hospital, University of Duisburg-Essen, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Schulze zur Wiesch","sequence":"additional","affiliation":[{"name":"University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria-Christina","family":"Jung","sequence":"additional","affiliation":[{"name":"Leberzentrum M\u00fcnchen, M\u00fcnchen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael P.","family":"Manns","sequence":"additional","affiliation":[{"name":"Hannover Medical School, Hannover, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Zeuzem","sequence":"additional","affiliation":[{"name":"University Hospital Frankfurt, Frankfurt am Main, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Sarrazin","sequence":"additional","affiliation":[{"name":"University Hospital Frankfurt, Frankfurt am Main, Germany"},{"name":"St. Josefs-Hospital Wiesbaden, Wiesbaden, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2020,9,18]]},"reference":[{"key":"ref2","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jhep.2018.07.002","article-title":"Challenges and perspectives of direct antivirals for the treatment of hepatitis C virus infection","volume":"69","author":"J Vermehren","year":"2018","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.jhep.2017.11.009","article-title":"Real-world effectiveness of 8-week treatment with ledipasvir\/sofosbuvir in chronic hepatitis C","volume":"68","author":"P Buggisch","year":"2018","journal-title":"J Hepatol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/apt.13925","article-title":"Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection","volume":"45","author":"M Cornberg","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/apt.15222","article-title":"Real\u2010world effectiveness and safety of glecaprevir\/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C\u2010Registry","volume":"49","author":"T Berg","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1053\/j.gastro.2017.11.007","article-title":"Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals","volume":"154","author":"J Dietz","year":"2018","journal-title":"Gastroenterology"},{"key":"ref7","first-page":"153","article-title":"EASL recommendations on treatment of hepatitis C 2016","volume":"66","author":"European Association for the Study of the Liver","year":"2016","journal-title":"J Hepatol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"M Bourli\u00e8re","year":"2017","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/cid\/civ973","article-title":"Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort","volume":"62","author":"C H\u00f6ner zu Siederdissen","year":"2016","journal-title":"Clin Infect Dis"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/apt.13769","article-title":"The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection","volume":"44","author":"J Vermehren","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"ref12","article-title":"EASL recommendations on treatment of hepatitis C 2018","author":"European Association for the Study of the Liver","year":"2018","journal-title":"J Hepatol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.jhep.2019.07.020","article-title":"Real-life effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in hepatitis c patients with previous DAA failure","volume":"71","author":"E Degasperi","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jhep.2019.06.002","article-title":"Effectiveness and safety of sofosbuvir\/velpatasvir\/voxilaprevir in patients with chronic hepatitis c previously treated with DAAs","volume":"71","author":"J Llaneras","year":"2019","journal-title":"J Hepatol"}],"container-title":["Zeitschrift f\u00fcr Gastroenterologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1217-7669.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T22:43:09Z","timestamp":1600468989000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1217-7669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":12,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2020,9,18]]},"published-print":{"date-parts":[[2020,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1217-7669","relation":{},"ISSN":["0044-2771","1439-7803"],"issn-type":[{"value":"0044-2771","type":"print"},{"value":"1439-7803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9]]}}}